Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levosulpiride + rabeprazole
- Development stage
- Unknown
- Lead developer
- Charan Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gutpride Plus is a fixed-dose combination medication containing levosulpiride and rabeprazole sodium. It is primarily used in the management of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), functional dyspepsia, and irritable bowel syndrome (IBS). Levosulpiride is a substituted benzamide that acts as a selective antagonist at dopamine D2 receptors in both the central and peripheral nervous systems, providing prokinetic effects by enhancing gastric emptying and intestinal transit. Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. The combination is designed to address both acid-related symptoms and impaired gastrointestinal motility.
- Brand names
- Gutpride Plus
- Other names
- levosulpiride and rabeprazole sodium capsules
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on levosulpiride + rabeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levosulpiride + rabeprazole.